Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey

Frantzen, Léa; Cohen, Jean-David; Tropé, Sonia; Beck, M.; Munos, Audrey; Sittler, Marie-Annick; Diebolt, Rita; Metzler, Isabelle; Sordet, Christelle

doi:10.1016/j.jbspin.2019.01.001

Cited by 33 publications

(48 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is important, as information and a good understanding on biosimilars seem to be associated with better adherence to biosimilars. 9 The new questions in the current survey showed that patients experience dissatisfaction in the quality and sufficiency of information and communication regarding biosimilars. Future research should clarify exactly what patients feel is missing, and how the missing information could be brought to the patients in the most efficient way.…”

Section: Discussionmentioning

confidence: 85%

“…Furthermore, it seems that patients with immune‐mediated inflammatory diseases may in general have poorer knowledge than oncology patients on biosimilar‐related topics. In a study 9 of over 600 French patients treated for rheumatic inflammatory diseases that assessed patients’ information about biosimilars, it was found that biosimilars were largely unknown to patients: 57% of the respondents did not know what biosimilars were. Respondents also worried about efficacy (60%), safety (57%) and non‐similar molecular structure (46%) compared with the originator.…”

Section: Discussionmentioning

confidence: 99%

“…While the questionnaire used in these surveys was not identical to ours, the results give an idea of differences in awareness between oncology patients and patients with immune‐mediated diseases. This is important, as information and a good understanding on biosimilars seem to be associated with better adherence to biosimilars 9 …”

Section: Discussionmentioning

confidence: 99%

“…This is important, as information and a good understanding on biosimilars seem to be associated with better adherence to biosimilars. 9…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

Peyrin–Biroulet

Lönnfors²,

Avedano³

et al. 2019

UEG Journal

View full text Add to dashboard Cite

Background and aims The aim of this survey was to find out whether the perspectives of patients with inflammatory bowel disease concerning biosimilars have changed since the publication of our last survey carried out in 2014–2015. Methods An online survey consisting of 19 questions was made available by the European Federation of Crohn’s and Ulcerative Colitis Associations between July 2018 and December 2018. Only respondents who had heard of biosimilars were asked to respond to all of the questions. Results In total, 1619 patients with inflammatory bowel disease responded the questionnaire. Most respondents were from Europe (79%), followed by Asia (8%), South America (7%) and Africa (5%). Some 44% of them had heard of biosimilars, and only these respondents continued to the biosimilar-specific questions. Respondents worried significantly more about biosimilars being less effective than the originator (50% in current and 39% in previous survey, p = 0.0004). However, respondents were more likely to believe that biosimilars will have an impact on the management of inflammatory bowel disease (75% in current and 62% in previous survey). Conclusions Many patients with inflammatory bowel disease remain unfamiliar with biosimilars. Although patients still worry about different aspects regarding biosimilars, they also tend to be more confident that biosimilars will have an impact on the management of their disease. More patient education is still needed to raise awareness about biosimilars.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…This is important, as information and a good understanding on biosimilars seem to be associated with better adherence to biosimilars. 9…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

Peyrin–Biroulet

Lönnfors²,

Avedano³

et al. 2019

UEG Journal

View full text Add to dashboard Cite

show abstract

“…However, switching means replacing a drug with which the clinical response was known, with another where the clinical response is still unknown [ 6 ]. That is why decisions to switch must be made for ethical reason on a case by case basis [ 17 ] and be supported by a medical decision that is shared with the patient [ 6 ].…”

Section: Resultsmentioning

confidence: 99%

Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?

Perpoil¹,

Grimandi

Birklé

et al. 2020

IJERPH

View full text Add to dashboard Cite

Biologic reference drugs and their copies, biosimilars, have a complex structure. Biosimilars need to demonstrate their biosimilarity during development but unpredictable variations can remain, such as micro-heterogeneity. The healthcare community may raise questions regarding the clinical outcomes induced by this micro-heterogeneity. Indeed, unwanted immune reactions may be induced for numerous reasons, including product variations. However, it is challenging to assess these unwanted immune reactions because of the multiplicity of causes and potential delays before any reaction. Moreover, safety assessments as part of preclinical studies and clinical trials may be of limited value with respect to immunogenicity assessments because they are performed on a standardised population during a limited period. Real-life data could therefore supplement the assessments of clinical trials by including data on the real-life use of biosimilars, such as switches. Furthermore, real-life data also include any economic incentives to prescribe or use biosimilars. This article raises the question of relevance of automating real life data processing regarding Biosimilars. The objective is to initiate a discussion about different approaches involving Machine Learning. So, the discussion is established regarding implementation of Neural Network model to ensure safety of biosimilars subject to economic incentives. Nevertheless, the application of Machine Learning in the healthcare field raises ethical, legal and technical issues that require further discussion.

show abstract

Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study

et al. 2021

View full text Add to dashboard Cite

In May 2019, the Government of British Columbia (BC) announced the implementation of the Biosimilars Initiative, mandating the switch of biologic (originator) drugs to biosimilars for certain patient populations in the hopes of optimizing public resources. Through this qualitative study, we aimed to identify patients’ perspectives as they undergo this change. From October 2019 to July 2020, we conducted nine pre- and six post-switch to biosimilar interviews with BC, English speaking participants, who were 18 years or older, and were currently taking a biologic medication. Participants were interviewed pre- and post-switch to a biosimilar medication and interviews were audio-recorded and transcribed verbatim for qualitative analysis. Interviews were thematically analysed and major themes and sub-categories were elucidated. The themes derived from pre and post-switch interviews captured participants’ anticipated or experienced barriers and enablers to the policy change. In general, the fears and apprehension of participants approaching the switch, including concerns surrounding the efficacy and safety of biosimilars, were addressed by their rheumatologist and social support circles. For the most part, participants were able to successfully manage their disease regardless of their baseline concerns about efficacy and safety. Experiences of changes in health delivery models were also observed secondary to the impact of the COVID-19 pandemic amongst participants. This study is the first of its kind to characterize the patient perspective regarding the BC Biosimilars Initiative. The incorporation of the patient perspective, including adequate provider-patient communication and shared decision-making can help to inform future non-medical switching policy changes.

show abstract

Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey

Cited by 33 publications

References 19 publications

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?

Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study

Contact Info

Product

Resources

About